<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The silencing of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes associated with increased DNA methylation of the promoter regions is a frequent observation in many forms of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Reactivation of these genes using pharmacological inhibitors of DNA methyltransferase such as <z:chebi fb="0" ids="50131">5-aza-2'-deoxycytidine</z:chebi> (<z:chebi fb="0" ids="50131">decitabine</z:chebi>) is a worthwhile therapeutic goal </plain></SENT>
<SENT sid="2" pm="."><plain>The effectiveness and tolerability of low-dose intravenous and subcutaneous <z:chebi fb="0" ids="50131">decitabine</z:chebi> regimens to demethylate and reactivate expression of the methylated gamma-<z:chebi fb="0" ids="5386">globin</z:chebi> gene in baboons and in patients with <z:e sem="disease" ids="C0002895" disease_type="Disease or Syndrome" abbrv="">sickle cell disease</z:e> led to successful trials of low-dose regimens of this drug in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Since these low-dose regimens are well-tolerated with minimal toxicity, they are suitable for <z:hpo ids='HP_0011010'>chronic</z:hpo> dosing to maintain promoter hypomethylation and expression of target genes </plain></SENT>
<SENT sid="4" pm="."><plain>The development of an orally administered therapy using DNA methyltransferase inhibitors would facilitate such <z:hpo ids='HP_0011010'>chronic</z:hpo> approaches to therapy </plain></SENT>
<SENT sid="5" pm="."><plain>We tested the ability of <z:chebi fb="0" ids="50131">decitabine</z:chebi> and a new salt derivative, <z:chebi fb="0" ids="50131">decitabine</z:chebi> mesylate, to reactivate the methylated gamma-<z:chebi fb="0" ids="5386">globin</z:chebi> gene in baboons when administered orally </plain></SENT>
<SENT sid="6" pm="."><plain>Our results demonstrate that oral administration of these drugs at doses 17-34 times optimal subcutaneous doses of <z:chebi fb="0" ids="50131">decitabine</z:chebi> reactivates fetal <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>, demethylates the epsilon- and gamma-<z:chebi fb="0" ids="5386">globin</z:chebi> gene promoters, and increases <z:chebi fb="0" ids="15358">histone</z:chebi> acetylation of these promoters in baboons (Papio anubis) </plain></SENT>
</text></document>